Press Releases

Date Title and Summary View
Toggle Summary Zosano Announces Positive Data from a Nonclinical Evaluation of Pharmacokinetics and Skin Tolerability Study for ADAM™ Technology for the Delivery of Zolmitriptan
Peer-reviewed article published in Journal of Pharmaceutical Science evaluates skin tolerability and bioavailability of ADAM’s intracutaneous zolmitriptan delivery FREMONT, Calif. , July 17, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company dedicated
View HTML
Toggle Summary Zosano to Present Additional Analyses from the ZOTRIP Pivotal Study on Pain Relief and Recurrence at the 2018 American Headache Society (AHS) Meeting
Key findings on receptor and binding kinetics also to be presented in a poster and oral presentation FREMONT, Calif. , June 27, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies that deliver rapid
View HTML
Toggle Summary Zosano Announces Publication on Adhesive Dermally-Applied Microarray (ADAM™) Technology for the Delivery of Zolmitriptan in Migraine in Journal of Pharmaceutics
Peer reviewed article evaluates effect of skin models on in vitro performance of ADAM FREMONT, Calif. , June 20, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic
View HTML
Toggle Summary Zosano Announces Publication of Most Bothersome Symptom Data from the ZOTRIP Pivotal Study in Headache: The Journal of Head and Face Pain
FREMONT, Calif. , May 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied
View HTML
Toggle Summary Zosano Appoints Steven A. Elms to Board of Directors
FREMONT, Calif. , May 22, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray
View HTML
Toggle Summary Zosano Pharma Reports First Quarter 2018 Financial Results and Operational Update
Completion of follow on offering netting $45.7 million Issuance of new US patent Long-term safety study now has 250 subjects enrolled FREMONT, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company
View HTML
Toggle Summary Zosano Reaches Another Enrollment Milestone in M207-ADAM Long-term Safety Study
250 subjects have enrolled in the Study The Study is set to complete enrollment on May 18th FREMONT, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company"), a clinical stage biopharmaceutical company focused on providing rapid systemic administration
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on First Quarter 2018 Financial Results and Provide Operational Update
FREMONT, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray
View HTML
Toggle Summary Zosano Announces Closing of Public Offering of Common Stock
FREMONT, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ADAM technology, today announced the closing of the previously
View HTML
Toggle Summary Zosano Pharma to Host Conference Call to Provide Operational Update
FREMONT, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today
View HTML